Short answer
Amneal Pharmaceuticals, Inc. (AMRX) filed an 8-K current report with the SEC on August 10, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement), Item 2.01 (Completion of Acquisition or Disposition of Assets), Item 2.03 (Creation of a Direct Financial Obligation), Item 3.02 (Unregistered Sales of Equity Securities), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). $350 million incremental term loan from Bank of America funded acquisition consideration.
Amneal Pharmaceuticals, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- $350 million incremental term loan from Bank of America funded acquisition consideration
- Debt increased through Amendment No. 3 Term Loan expansion under Amneal’s existing credit agreement
- JPMorgan Chase served as administrative agent for the amended facility
- Stockholders Agreement amended to recognize acquisition-issued shares within Amneal Group ownership
- Share ownership clarification affects governance and rights under the stockholders agreement
Item 3.02 · Unregistered Sales of Equity Securities
- Amneal issued 28,942,098 Class A shares to acquisition sellers as stock consideration
- Transaction used Section 4(a)(2) private-placement exemption, avoiding immediate Securities Act registration
- Seller resale registration required on Form S-3 by the later of 30 days after closing or 10 business days after seller information receipt
- Potential future resale supply could pressure AMRX shares once registration becomes effective
Item 7.01 · Regulation FD Disclosure
- Amneal completed the Acquisition, marking a transition from announced transaction to closed deal
- Exhibit 99.1 press release contains transaction details and expected strategic implications
- Investors should assess acquisition funding, integration requirements, and potential effects on future financial results
Item EX-99.1 · Exhibit EX-99.1
- Completed Kashiv acquisition, creating an integrated biosimilars platform spanning R&D, manufacturing, and commercialization
- Biosimilars become a major long-term growth pillar, extending Amneal’s growth profile into the 2030s
- Access to global biologics market facing more than $300 billion of projected loss-of-exclusivity over the next decade
- Combined portfolio expected to support multiple biosimilar launches annually
- Key execution risks: Kashiv integration, regulatory approvals, commercialization timing, competition, pricing pressure, and Amneal’s indebtedness
Other items in this filing:
- Item 2.01: Completion of Acquisition or Disposition of Assets
- Item 2.03: Creation of a Direct Financial Obligation
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Amneal Pharmaceuticals, Inc. 8-K filings
Get the next AMRX 8-K as it lands
Follow AMRX for push alerts, or ask the research agent what this filing means.